Alpha Teknova Inc

Alpha Teknova Inc(TKNO)股票分析

$8.090

+0.237 (+2.93%)收盘时

Loading chart…
最高
8.180
开盘
7.880
成交量加权均价
8.05
成交量
679.70K
市值
56.74M
最低
7.880
成交额
5.47M
企业价值/息税折旧摊销前利润(TTM)
-74.76

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.

AI 分析 of Alpha Teknova Inc (TKNO)

买入

Alpha Teknova Inc (TKNO) appears to be a good buy right now. The current price is $6.42, and analysts have set a price target of $9, indicating a potential upside of approximately 40%. The company reported a significant revenue growth of 18% in Q2 2026, reaching over $12 million, which is the highest quarterly revenue in its history. However, there is a risk with the forward P/E ratio being 0, indicating uncertainty in future earnings expectations.

估值指标

Alpha Teknova Inc(TKNO)当前预期市盈率为 0.00,5 年平均预期市盈率为 -9.30。

预期市盈率

高估
5 年均值 P/E
-9.30
当前P/E
0.00
高估
-2.59
低估
-16.01

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
-20.23
当前EV/EBITDA
-74.76
高估
-2.49
低估
-37.97

预期市销率

合理
5 年均值 P/S
5.51
当前P/S
8.33
高估
8.87
低估
2.15

Alphio AI 对 TKNO 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%TKNO

$8.06

情景价格

基

基准

基准 · 50%TKNO

$7.23

情景价格

悲

悲观

悲观 · 25%TKNO

$7.04

情景价格

持有 TKNO 的大户

A

Apollo Global Management, Inc.

+ 持有TKNO

-18.35%

3个月收益率

事件时间线

2026-10-20 (ET)

20:00:00

Treasury Yields Retreat as Netflix Falls Over 5%

16:30:00

Teknova Estimates Total Revenue Up 19% to 21%

16:30:00

Alpha Teknova Commences Underwritten Public Offering of Common Stock

2026-10-02 (ET)

16:30:00

Alpha Teknova and Pluristyx Complete Drug Master File for PluriFreeze System

2026-05-06 (ET)

16:40:00

Teknova Q1 Revenue $11.08M Beats Consensus

资讯

TKNO 常见问题 —— 由 Alphio AI 解答

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Alpha Teknova Inc (TKNO) appears to be a good buy right now. The current price is $6.42, and analysts have set a price target of $9, indicating a potential upside of approximately 40%. The company reported a significant revenue growth of 18% in Q2 2026, reaching over $12 million, which is the highest quarterly revenue in its history. However, there is a risk with the forward P/E ratio being 0, indicating uncertainty in future earnings expectations.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易